DjiboutiTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.76–1.4) 120 (87–159)
Mortality (HIV+TB only) 0.14 (0.12–0.17) 16 (13–19)
Prevalence  (includes HIV+TB) 8.7 (4.6–14) 996 (530–1 605)
Incidence  (includes HIV+TB) 5.4 (4.8–6.1) 619 (547–696)
Incidence (HIV+TB only) 0.54 (0.44–0.65) 62 (51–74)
         
Case detection, all forms (%) 41 (36–46)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
18 (3–33) 29 (8–51)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 069   165
Pulmonary, clinically diagnosed      
Extrapulmonary 986    
       
Total new and relapse 2 220    
Previously treated, excluding relapses 7    
Total cases notified 2 227    
Among 1 069 new cases:
51 (5%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 218 (20%) 28 (16%) 218
Laboratory-confirmed RR-/MDR-TB cases     110
Patients started on MDR-TB treatment ***     60
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 877 (84)
HIV-positive TB patients 160 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 109 (68)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (75) 1 383
Previously treated cases, excluding relapse, registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 5.7
Drug susceptibility testing (per 5 million population) 5.7
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 3.1
% Funded domestically  
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-01 Data: www.who.int/tb/data